News
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback